AB
AKRO

Amalgamated Bank’s Akero Therapeutics AKRO Stock Holding History

Amalgamated Bank’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,265
Closed -$108K – 2971
2025
Q3 		$108K Sell
2,265
-305
-12% -$14.8K ﹤0.01% 1688
2025
Q2 		$137K Hold
2,570
– – ﹤0.01% 1646
2025
Q1 		$104K Buy
2,570
+410
+19% +$17.4K ﹤0.01% 1670
2024
Q4 		$60K Hold
2,160
– – ﹤0.01% 1795
2024
Q3 		$62K Hold
2,160
– – ﹤0.01% 1787
2024
Q2 		$51K Buy
2,160
+83
+4% +$1.77K ﹤0.01% 1847
2024
Q1 		$52K Sell
2,077
-5,247
-72% -$126K ﹤0.01% 1854
2023
Q4 		$171K Sell
7,324
-235
-3% -$4.63K ﹤0.01% 1841
2023
Q3 		$382K Buy
7,559
+1,166
+18% +$54.3K ﹤0.01% 1542
2023
Q2 		$298K Buy
6,393
+2,634
+70% +$121K ﹤0.01% 1672
2023
Q1 		$144K Sell
3,759
-844
-18% -$37.6K ﹤0.01% 1918
2022
Q4 		$252K Buy
4,603
+954
+26% +$40.9K ﹤0.01% 1766
2022
Q3 		$124K Buy
3,649
+152
+4% +$2.33K ﹤0.01% 2055
2022
Q2 		$33K Sell
3,497
-422
-11% -$4.4K ﹤0.01% 2659
2022
Q1 		$56K Buy
+3,919
New +$68.6K ﹤0.01% 2419

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Amalgamated Bank's AKRO Position: Q4 2025 in Review

Amalgamated Bank sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 2,265 shares — an estimated $108K sold.

Amalgamated Bank first reported a position in AKRO in Q1 2022 and held it in 15 quarters. The position peaked at $382K in Q3 2023. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Amalgamated Bank reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Amalgamated Bank sold 2,265 Akero Therapeutics shares in Q4 2025, an estimated $108K.
  • Amalgamated Bank first reported a position in Akero Therapeutics in Q1 2022 and held it in 15 quarters.
  • Amalgamated Bank's Akero Therapeutics position peaked at $382K in Q3 2023.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Amalgamated Bank's 13F filing for Q4 2025, filed 5 Feb 2026.